# A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Source: https://onco.cc/trials/nct06500026/  
OnCo record `nct06500026` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Izalontamab brengitecan, Topotecan in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) is a phase 3 interventional study registered as NCT06500026 by Sichuan Baili Pharmaceutical Co., Ltd., with 722 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, Topotecan. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06500026
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 722

## Sources

- ClinicalTrials.gov NCT06500026: https://clinicaltrials.gov/study/NCT06500026

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct06500026.json